Back

PHLDA2 promotes breast cancer metastasis by co-opting a developmental program for placental vascular remodeling

Halas, P. V.; Savage, H.; Hachey, S. J.; Lev, T.; Prem Antony Samy, A. L.; Chan, C.; Jimenez, S.; Domadia, R. M.; Lin, I.; Mallya, S.; Insua-Rodriguez, J.; Gonzalez, J.; Adam, I.; Alshetaiwi, H.; Hernandez, G. A.; Longworth, A.; McMullen, T. P.; Kessenbrock, K.; Hughes, C. C.; Ma, D.; Lawson, D. A.

2025-08-23 cancer biology
10.1101/2025.08.19.670946 bioRxiv
Show abstract

Identifying drivers of metastasis is essential for developing new treatments for patients with advanced disease. Here, we identify PHLDA2 as a robust driver of breast cancer metastasis. Previous work established PHLDA2 as an imprinted gene expressed by trophoblasts which are critical for vascular remodeling during placental development. We find that hypomethylation of PHLDA2 in breast tumors correlates with increased gene expression, which is associated with metastasis and poor survival in breast cancer patients. RNA-sequencing showed that PHLDA2 overexpression results in upregulation of genes that control invasion, extracellular matrix assembly, and vascular remodeling, consistent with trophoblast functions in placental development. Using an in vitro vascularized microtumor (VMT) system, we find that PHLDA2 functions through SPARC, which promotes metastasis by inducing vascular permeability and enhancing tumor dissemination. These data suggest that increased expression of PHLDA2 through hypomethylation promotes metastasis by ectopic expression of a developmental program for vascular remodeling.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.